Form 4 for ANIK Anika Therapeutics, Inc.
Accepted 2023-06-16 00:00:00 ET · period of report 2023-06-14 · accession 0001171843-23-003959 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-06-16 | 2023-06-14 | ANIK | HENNEMAN JOHN B III | Dir | A - Grant | $0.00 | +6,500 | 29.9K | +28% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-06-14 | A | A | 6,500 | $0.00 | 29,936 | D | — | — | (F1) These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2024 annual meeting of the Company's stockholders or June 14, 2024. |